We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 21, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Bendamustine cyclopolysaccharide compositions
Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
Polymers with complex macromolecular architecture having flame-retardant properties
Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
Ophthalmic compositions containing a nitric oxide donor
NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS
Pharmaceutical compositions for the treatment of muscular disorders
Composition comprising iota-carrageenan against viral Conjunctivitis
Substituted thiazole or oxazole as P2X7 receptor antagonists
Amorphous form of a thiocolchicine derivative
Cyclic beta defensins analogs for the treatment of infections
Nitric oxide donating carnosine compounds